Piramal Pharma Limited
PPLPHARMA.BO
Bombay Stock Exchange177.90
INR
+2.00
- -
Piramal Pharma Limited
PPLPHARMA.BO
(Bombay Stock Exchange)
Recent
price
177.90
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Piramal Pharma Limited (NSE: PPLPHARMA, BSE: 543635) is a global pharmaceutical company that offers a portfolio of differentiated contract development and manufacturing organization services, complex hospital generics, and consumer healthcare products through 17 development and manufacturing facilities and a distribution network spanning over 100 countries; Piramal Pharma Solutions provides end-to-end drug lifecycle solutions including highly potent active pharmaceutical ingredients, finished dosage forms, antibody-drug conjugates via its ADCelerate platform, sterile injectables, biologics, vaccines, peptides, and potent oral solids across sites in North America, Europe, and Asia; Piramal Critical Care specializes in inhaled anesthetics such as Sevoflurane, intrathecal Baclofen, and other hospital generics with leading market shares in the US and presence in Europe and rest-of-world markets; Piramal Consumer Healthcare markets over-the-counter brands including Little's, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri-Activ in India, targeting self-care and wellness segments. Incorporated in 2020 and headquartered in Mumbai, India, as part of the Piramal Group, the company serves pharmaceutical innovators, hospitals, group purchasing organizations, and consumers primarily in the United States, Europe, Japan, India, and internationally, with associates including AbbVie Therapeutics India Private Limited for ophthalmology products and a minority stake in Yapan Bio for biologics. Recent developments include crossing $1 billion in FY2025 revenues with 12% year-over-year growth and 17% EBITDA margins, a $90 million investment announced in June 2025 to expand US facilities in Lexington, Kentucky, and Riverview, Michigan, for enhanced sterile injectables and antibody-drug conjugate manufacturing capacity expected operational by late 2025 and 2027 respectively, major US GPO contract renewals and order wins for inhalation anesthetics, completion of India capacity expansions for Sevoflurane commercialization targeting a $400 million rest-of-world opportunity, and addition of 21 new consumer products with power brands achieving 20% growth.